# gpqa-recm7S5Gq7FWCgaHZ

Run: gpqa-main-ours-8gpu; arm: ours.

Expected: A
Model answer: B
Scoring outcome: wrong extracted answer; answer source: after_thinking_end.

## Question

A researcher is investigating the role of the PI3K/MTOR pathway in breast cancer cell survival and proliferation. They proceed to treat MCF7 cells with a variety drugs that block components of the pathway as follows:

1)  DMSO (Control)
2)  2 uM MK2206 
3)  5 uM GDC-0941
4)  1 nM Rapamycin
5)  1 nM Rapalink-1
6)  1 uM AZD8055
7)  0.5 uM GSK2126458
8)  2 uM MK2206 + 1 nM Rapalink-1 
9)  2 uM MK2206 + 1 nM Rapamycin
10) 2 uM MK2206 + 1 uM AZD8055 
11) 5 uM GDC-0941 + 1 nM Rapalink-1
12) 5 uM GDC-0941 + 1 nM Rapamycin 
13) 5 uM GDC-0941 + 1 uM AZD8055  

All of these treatments were administered with a full medium (containing serum) refresh with the cells maintained at 37degC and 5% CO2 for the duration of the treatments. Assume all drugs were applied at concentrations that completely inhibit their targets and that off-targets at these concentrations are minimal. At a 6 hour time point cell lysates were prepared for all of these treatment conditions. At a 48 hour time point CyQuant Direct was used to determine the fraction of live cells relative to control (control set to 100%). Western blots were performed on the lysates harvested at 6 hours for various phospho proteins in the pathway to determine the effect of these drugs on cell signaling. Assume this is enough time for full signal propagation to downstream pathway members. For the western blots phospho sites as well as corresponding total proteins were probed for each condition. These signals were normalized to each other (i.e. pSer473 Akt signal was divided by the Akt signal). These normalized values were then expressed as a percentage of the control values (control set to 100%). Below are the live cell and phospho site signal values expressed as a percentage of control for each condition in the following order: Live cell / pSer473 Akt / pThr308 Akt / pThr246 PRAS40 / pThr37 & pThr46 4E-BP1 / pThr389 S6K

1) 100 / 100 / 100 / 100 / 100 / 100
2) 70 / 0 / 0 / 0 / 70 / 30
3) 40 / 0 / 0 / 0 / 30 / 0
4) 80 / 250 / 250 / 150 / 100 / 0
5) 60 / 250 / 250 / 150 / 0 / 0
6) 50 / 0 / 250 / 150 / 0 / 0
7) 2 / 0 / 0 / 0 / 0 / 0
8) 7 / 0 / 0 / 0 / 0 / 0
9) 60 / 0 / 0 / 0 / 70 / 0
10) 5 / 0 / 0 / 0 / 0 / 0
11) 3 / 0 / 0 / 0 / 0 / 0
12) 40 / 0 / 0 / 0 / 30 / 0
13) 2 / 0 / 0 / 0 / 0 / 0    

Which kinases of the PI3K/MTOR pathway transmit the majority of the effect on cell proliferation and survival in MCF7?

(A) AKT1/2/3 (assume full redundancy of isoform function) and mTORC1
(B) PIK3CA/B/C/D (assume full redundancy of isoform function) and mTORC1
(C) AKT1/2/3 (assume full redundancy of isoform function) and mTORC2
(D) mTORC1 and mTORC2

## Final response

```text


The data from the experiments show that cell survival (measured by live cell percentage relative to control) is most significantly reduced by inhibitors of PI3K (e.g., GSK2126458, which gives 2% live cells) compared to inhibitors of mTORC1 (e.g., Rapamycin, 80% live cells; MK2206, 70% live cells; AZD8055, 50% live cells) or mTORC2 (e.g., Rapalink-1, 60% live cells). This indicates that PI3K inhibition has the greatest impact on cell survival and proliferation in MCF7 cells.

The phospho-site data further support this. PI3K inhibition (e.g., GDC-0941) results in near-complete loss of Akt phosphorylation (pSer473 Akt and pThr308 Akt at 0%), while mTORC1 inhibition (e.g., Rapamycin) results in high Akt phosphorylation (pSer473 Akt and pThr308 Akt at 250%), indicating that mTORC1 does not directly affect Akt phosphorylation. The combination of PI3K and mTORC1 inhibition (e.g., GDC-0941 + AZD8055) further reduces survival to 2%, showing that both components contribute, but PI3K is the primary driver of the survival effect.

Among the options:
- (A) AKT1/2/3 and mTORC1: AKT is downstream of PI3K, and the data show that PI3K inhibition has a larger effect than AKT inhibition (though direct AKT inhibitors are not tested here). mTORC1 inhibition has a moderate effect on survival, but PI3K is more critical.
- (B) PIK3CA/B/C/D and mTORC1: PIK3CA/B/C/D represent the catalytic subunits of PI3K (the kinase responsible for initiating the pathway). PI3K inhibition has the strongest effect on survival, and mTORC1 inhibition adds to the effect, making this the best fit for transmitting the majority of the effect.
- (C) AKT1/2/3 and mTORC2: mTORC2 inhibition (Rapalink-1) has a minimal effect on survival (60% live cells), so it does not transmit the majority of the effect.
- (D) mTORC1 and mTORC2: Both have less impact on survival than PI3K inhibition, with mTORC2 having a particularly small effect.

Thus, PIK3CA/B/C/D (PI3K) transmits the majority of the effect on cell proliferation and survival, with mTORC1 playing a supporting role. Option (B) correctly identifies PIK3CA/B/C/D and mTORC1 as the kinases involved.

Final answer: (B)
```

## Full generated reasoning and answer

```text
First, I need to understand the question. It's asking which kinases in the PI3K/MTOR pathway transmit the majority of the effect on cell proliferation and survival in MCF7 cells. The options are:

(A) AKT1/2/3 and mTORC1

(B) PIK3CA/B/C/D and mTORC1

(C) AKT1/2/3 and mTORC2

(D) mTORC1 and mTORC2

I have data from experiments where different drugs were used to block components of the pathway. The drugs target specific parts:

- DMSO (Control) is condition 1.

- 2 uM MK2206: I think this inhibits mTORC1, but I need to recall what these drugs do.

Let me list out what each drug does based on standard knowledge:

- MK2206: This is a specific inhibitor of mTORC1. It's a dual mTORC1/mTORC2 inhibitor, but I think it's known for inhibiting mTORC1. Actually, upon second thought, MK2206 is a selective inhibitor of mTORC1, but it might have some effect on mTORC2. I should look at the data to infer.

The problem says: "Assume all drugs were applied at concentrations that completely inhibit their targets and that off-targets at these concentrations are minimal." So I can trust that the drugs are specific.

Let me recall common inhibitors:

- MK2206: Inhibits mTORC1 (specifically, it's a mTORC1 inhibitor, but it might inhibit mTORC2 as well? I think MK2206 is a dual inhibitor, but in many contexts, it's used for mTORC1 inhibition. Wait, no, I remember that MK2206 is a selective inhibitor of mTORC1, but it has some effect on mTORC2. Let's see the data.

Perhaps I should look at the data to deduce.

List of conditions with their values:

1) DMSO (Control): 100 / 100 / 100 / 100 / 100 / 100

2) 2 uM MK2206: 70 / 0 / 0 / 0 / 70 / 30

3) 5 uM GDC-0941: 40 / 0 / 0 / 0 / 30 / 0

4) 1 nM Rapamycin: 80 / 250 / 250 / 150 / 100 / 0

5) 1 nM Rapalink-1: 60 / 250 / 250 / 150 / 0 / 0

6) 1 uM AZD8055: 50 / 0 / 250 / 150 / 0 / 0

7) 0.5 uM GSK2126458: 2 / 0 / 0 / 0 / 0 / 0

8) 2 uM MK2206 + 1 nM Rapalink-1: 7 / 0 / 0 / 0 / 0 / 0

9) 2 uM MK2206 + 1 nM Rapamycin: 60 / 0 / 0 / 0 / 70 / 0

10) 2 uM MK2206 + 1 uM AZD8055: 5 / 0 / 0 / 0 / 0 / 0

11) 5 uM GDC-0941 + 1 nM Rapalink-1: 3 / 0 / 0 / 0 / 0 / 0

12) 5 uM GDC-0941 + 1 nM Rapamycin: 40 / 0 / 0 / 0 / 30 / 0

13) 5 uM GDC-0941 + 1 uM AZD8055: 2 / 0 / 0 / 0 / 0 / 0

First, I need to know what each drug inhibits.

Standard knowledge:

- Rapamycin (Sirolimus): Inhibits mTORC1, but not mTORC2 (initially, but with chronic exposure, it can affect mTORC2, but here it's short term, 6 hours, so probably mTORC1 inhibition).

- Rapalink-1: I think this is a mTORC2 inhibitor. Rapalink-1 is a specific inhibitor of mTORC2, I believe. Rapalink-1 is a compound that inhibits mTORC2.

- AZD8055: This is a mTORC1 inhibitor. AZD8055 is a specific mTORC1 inhibitor.

- GSK2126458: This is a PI3K inhibitor. GSK2126458 inhibits PI3K.

- GDC-0941: Also a PI3K inhibitor.

- MK2206: This is a mTORC1 inhibitor. MK2206 is a selective inhibitor of mTORC1.

Let me confirm:

- MK2206: Inhibits mTORC1 (and has some effect on mTORC2, but often considered mTORC1 inhibitor).

- Rapamycin: Inhibits mTORC1 (mTORC1 inhibitor).

- Rapalink-1: I think Rapalink-1 is a mTORC2 inhibitor. Upon recall, Rapalink-1 (also known as RapaLink-1) is a specific inhibitor of mTORC2.

- AZD8055: This is a mTORC1 inhibitor. AZD8055 is a selective inhibitor of mTORC1.

- GDC-0941: PI3K inhibitor (specifically, it inhibits PI3K).

- GSK2126458: PI3K inhibitor.

In the data, for condition 4: Rapamycin (1 nM) gives pSer473 Akt = 250%, which is high. That suggests that Rapamycin does not inhibit Akt phosphorylation at Ser473.

pSer473 Akt is phosphorylated by mTORC2, I think. In the PI3K pathway, Akt is phosphorylated at Thr308 by PDK1, and at Ser473 by mTORC2.

Standard: Akt activation: PI3K activates PDK1, which phosphorylates Akt at Thr308. Then mTORC2 phosphorylates Akt at Ser473.

So, if mTORC2 is inhibited, pSer473 Akt should be low, but pThr308 Akt might be high if PDK1 is active.

In condition 4: Rapamycin (mTORC1 inhibitor) gives pSer473 Akt = 250%, which is above control. That seems odd.

Control is 100%, so 250% means higher than control? But that doesn't make sense for an inhibitor.

Let's read the values: "normalized values were then expressed as a percentage of the control values (control set to 100%)"

So for Rapamycin (cond 4): pSer473 Akt = 250%, pThr308 Akt = 250%, pThr246 PRAS40 = 150%, pThr37 & pThr46 4E-BP1 = 100%, pThr389 S6K = 0%

pThr389 S6K is phosphorylated by mTORC1, so if it's 0%, that means mTORC1 is inhibited.

pSer473 Akt is 250%, which is high. But Rapamycin inhibits mTORC1, not mTORC2. mTORC2 is not inhibited by Rapamycin in short term.

In fact, Rapamycin specifically inhibits mTORC1 but not mTORC2, so mTORC2 should still be active, so pSer473 Akt should be high.

In many cells, Rapamycin causes a decrease in pSer473 Akt over time, but in short term (6 hours), it might not be affected because mTORC2 is not inhibited.

I think for Rapamycin, at short time points, pSer473 Akt remains high because mTORC2 is intact.

Similarly, in condition 5: Rapalink-1 (mTORC2 inhibitor) gives pSer473 Akt = 250%? No, condition 5: 60 / 250 / 250 / 150 / 0 / 0

So pSer473 Akt = 250%, pThr308 Akt = 250%, pThr246 PRAS40 = 150%, pThr37 & pThr46 4E-BP1 = 0%, pThr389 S6K = 0%

pThr37 & pThr46 4E-BP1 is 0%, which is phosphorylated by mTORC1, so mTORC1 is inhibited.

pThr389 S6K is also 0%, which is mTORC1-dependent.

But pSer473 Akt is 250%, which is high. That suggests mTORC2 is active.

Rapalink-1 is a mTORC2 inhibitor, so if it inhibits mTORC2, pSer473 Akt should be low, but here it's 250%, so that means Rapalink-1 is not inhibiting mTORC2 in this context? Or perhaps I have the drug wrong.

I think I have a mistake.

Let me look up standard inhibitors.

Perhaps for MCF7 cells, there is something specific.

Another thought: in some cells, the baseline pSer473 Akt is high, but here control is 100%, so for Rapalink-1, it should be low.

Let's read the problem again.

In condition 5: 1 nM Rapalink-1: 60 / 250 / 250 / 150 / 0 / 0

So live cell 60%, pSer473 Akt 250%, pThr308 Akt 250%, pThr246 PRAS40 150%, pThr37 & pThr46 4E-BP1 0%, pThr389 S6K 0%

pThr37 & pThr46 4E-BP1 is 0%, which is phosphorylated by mTORC1, so mTORC1 is inhibited.

pThr389 S6K is 0%, also mTORC1.

But pSer473 Akt is 250%, which is high, so mTORC2 is active.

But Rapalink-1 is supposed to be a mTORC2 inhibitor. If it inhibits mTORC2, pSer473 Akt should be low, but here it's high, so perhaps Rapalink-1 is not inhibiting mTORC2 in this assay, or it's a different drug.

I think I have the drug names mixed up.

Let me try to recall what Rapalink-1 is.

Upon second thought, Rapalink-1 is a compound that inhibits mTORC2, but in some contexts, it might not be specific.

Perhaps for this problem, we should use the data to infer.

Let's look at the live cell percentages.

Live cell is the fraction of live cells relative to control, set to 100% for control.

So lower live cell percentage means more cell death or less proliferation.

For example, condition 7: GSK2126458 (PI3K inhibitor) gives live cell 2%, very low.

Condition 10: 2 uM MK2206 + 1 uM AZD8055: live cell 5%

 Etc.

Now, the key is to see which drugs affect which parts.

Let's group the drugs by what they inhibit.

First, PI3K inhibitors: GDC-0941 and GSK2126458.

GDC-0941 is a PI3K inhibitor, GSK2126458 is also a PI3K inhibitor.

In condition 3: 5 uM GDC-0941: live cell 40%, pSer473 Akt 0%, pThr308 Akt 0%, pThr246 PRAS40 0%, pThr37 & pThr46 4E-BP1 30%, pThr389 S6K 0%

pThr37 & pThr46 4E-BP1 is 30%, which is low, but not zero. 4E-BP1 phosphorylation is by mTORC1, so if it's 30%, mTORC1 is partially active.

pThr389 S6K is 0%, so mTORC1 is inhibited.

But pSer473 Akt and pThr308 Akt are 0%, which suggests Akt is not phosphorylated.

GDC-0941 inhibits PI3K, so it should reduce Akt phosphorylation.

In condition 4: Rapamycin (mTORC1 inhibitor): live cell 80%, pSer473 Akt 250%, pThr308 Akt 250%, pThr246 PRAS40 150%, pThr37 & pThr46 4E-BP1 100%, pThr389 S6K 0%

pThr389 S6K is 0%, which is mTORC1-dependent, so mTORC1 is inhibited.

pThr37 & pThr46 4E-BP1 is 100%, which is normal, but 4E-BP1 phosphorylation is by mTORC1, so if it's 100%, it means mTORC1 is active? Contradiction.

pThr37 & pThr46 4E-BP1 is phosphorylated by mTORC1, so if it's 100% in Rapamycin condition, that means mTORC1 is not inhibited, but Rapamycin inhibits mTORC1.

This is confusing.

I think I have a mistake in the interpretation.

Let's read the phospho sites carefully.

The phospho sites are:

- pSer473 Akt: phosphorylation of Akt at Ser473

- pThr308 Akt: phosphorylation of Akt at Thr308

- pThr246 PRAS40: phosphorylation of PRAS40 at Thr246 (by mTORC1)

- pThr37 & pThr46 4E-BP1: phosphorylation of 4E-BP1 at Thr37 and Thr46 (by mTORC1)

- pThr389 S6K: phosphorylation of S6K at Thr389 (by mTORC1)

In Rapamycin condition (cond 4), pThr389 S6K = 0%, which is correct for mTORC1 inhibition.

pThr37 & pThr46 4E-BP1 = 100%, but 4E-BP1 phosphorylation is by mTORC1, so if mTORC1 is inhibited, it should be low, not 100%.

This is a problem.

Unless in this assay, the phosphorylation is measured differently.

Perhaps for 4E-BP1, the phosphorylation at Thr37/46 is not directly by mTORC1 in all contexts, but I think it is.

Another possibility: the "pThr37 & pThr46 4E-BP1" is the phosphorylated form, so if it's 100%, it means it's fully phosphorylated, but in mTORC1 inhibition, it should be dephosphorylated.

In Rapamycin, 4E-BP1 is dephosphorylated, so the signal should be low.

But here it's 100%, which is high.

Let's look at the values for Rapamycin: pThr37 & pThr46 4E-BP1 = 100%, pThr389 S6K = 0%

pThr389 S6K = 0% means no phosphorylation, so mTORC1 is inhibited.

But pThr37 & pThr46 4E-BP1 = 100% means it's phosphorylated, which should not be the case.

Unless in this cell type, 4E-BP1 is phosphorylated by other kinases, but I doubt it.

Another idea: perhaps the "pThr37 & pThr46 4E-BP1" is the phosphorylated form, and in the absence of mTORC1, it is dephosphorylated, so the signal should be low. But here it's 100%, so for Rapamycin, it's high, which is wrong.

Let's check condition 5: Rapalink-1: 60 / 250 / 250 / 150 / 0 / 0

pThr37 & pThr46 4E-BP1 = 0%, which is low, so mTORC1 is inhibited.

pThr389 S6K = 0%, also low.

pSer473 Akt = 250%, high.

Rapalink-1 is a mTORC2 inhibitor, so if it inhibits mTORC2, pSer473 Akt should be low, but here it's 250%, high, so that suggests that Rapalink-1 is not inhibiting mTORC2, or it's a different drug.

I think I have a confusion with the drug names.

Let me search my memory.

Upon recall, Rapamycin (Sirolimus) is an mTORC1 inhibitor.

Rapalink-1 is a compound that inhibits mTORC2. Rapalink-1 is also known as a mTORC2 inhibitor.

But in the data, for Rapalink-1, pSer473 Akt is high, which is inconsistent with mTORC2 inhibition.

Unless in MCF7 cells, there is a baseline high pSer473 Akt, but Rapalink-1 should reduce it.

Perhaps for this problem, we should not rely on external knowledge and use the data to infer.

Let's list all conditions and see the effects.

First, control (1): 100 / 100 / 100 / 100 / 100 / 100

Condition 2: 2 uM MK2206: 70 / 0 / 0 / 0 / 70 / 30

MK2206 is a mTORC1 inhibitor, so we expect pThr389 S6K and pThr37/46 4E-BP1 to be low, but here pThr37/46 4E-BP1 = 70%, pThr389 S6K = 30%, which is not low, but 70% and 30% are less than 100%, so it's reduced, but not zero.

pThr37/46 4E-BP1 = 70%, pThr389 S6K = 30%, so mTORC1 is partially inhibited.

pSer473 Akt = 0%, which is low.

Condition 3: 5 uM GDC-0941 (PI3K inhibitor): 40 / 0 / 0 / 0 / 30 / 0

pSer473 Akt = 0%, pThr308 Akt = 0%, pThr246 PRAS40 = 0%, pThr37/46 4E-BP1 = 30%, pThr389 S6K = 0%

So for PI3K inhibitor, Akt phosphorylation is low, but 4E-BP1 phosphorylation is 30%, which is low, but not zero.

Condition 4: 1 nM Rapamycin (mTORC1 inhibitor): 80 / 250 / 250 / 150 / 100 / 0

pThr37/46 4E-BP1 = 100%, pThr389 S6K = 0%

pThr389 S6K = 0% means mTORC1 inhibited.

pThr37/46 4E-BP1 = 100% means it's phosphorylated, which should not happen if mTORC1 is inhibited. This is the key point.

I think there might be a misunderstanding of the phospho sites.

Upon standard knowledge, 4E-BP1 is phosphorylated by mTORC1, and when phosphorylated, it releases eIF4G, so in mTORC1 inhibition, 4E-BP1 is dephosphorylated.

But here for Rapamycin, it's 100%, so it's phosphorylated, which is wrong.

Unless the "pThr37 & pThr46 4E-BP1" is the dephosphorylated form or something, but the problem says "pThr37 & pThr46 4E-BP1" so it's the phosphorylated form.

Perhaps in this assay, the values are reported as the percentage of phosphorylated protein, so for Rapamycin, it should be low.

But the data shows 100% for Rapamycin, which is high.

Let's look at condition 5: Rapalink-1: 60 / 250 / 250 / 150 / 0 / 0

pThr37/46 4E-BP1 = 0%, so dephosphorylated, which means mTORC1 is inhibited.

pThr389 S6K = 0%, also inhibited.

pSer473 Akt = 250%, high.

Rapalink-1 is a mTORC2 inhibitor, so if it inhibits mTORC2, pSer473 Akt should be low, but here it's high, so that suggests that Rapalink-1 is not inhibiting mTORC2, or it's a different drug.

I recall that Rapalink-1 is a specific inhibitor of mTORC2, but in some contexts, it might not be.

Perhaps for this problem, we should focus on the live cell data and the phospho signals to see which kinases are critical for proliferation.

The question is: "which kinases of the PI3K/MTOR pathway transmit the majority of the effect on cell proliferation and survival"

So, for cell proliferation and survival, we look at live cell percentage.

Lower live cell percentage means less survival/proliferation.

Also, from the phospho data, we see which signals are affected.

Let's see the effect of each drug on live cell.

Control: 100%

Condition 2: MK2206 (mTORC1 inhibitor): 70% live cell

Condition 3: GDC-0941 (PI3K inhibitor): 40% live cell

Condition 4: Rapamycin (mTORC1 inhibitor): 80% live cell

Condition 5: Rapalink-1 (mTORC2 inhibitor): 60% live cell

Condition 6: AZD8055 (mTORC1 inhibitor): 50% live cell

Condition 7: GSK2126458 (PI3K inhibitor): 2% live cell

Condition 8: MK2206 + Rapalink-1: 7% live cell

Condition 9: MK2206 + Rapamycin: 60% live cell

Condition 10: MK2206 + AZD8055: 5% live cell

Condition 11: GDC-0941 + Rapalink-1: 3% live cell

Condition 12: GDC-0941 + Rapamycin: 40% live cell

Condition 13: GDC-0941 + AZD8055: 2% live cell

First, PI3K inhibitors: GDC-0941 and GSK2126458 both reduce live cell to low levels.

GSK2126458 (cond 7): 2% live cell

GDC-0941 (cond 3): 40% live cell

GDC-0941 + Rapalink-1 (cond 11): 3% live cell

GDC-0941 + Rapamycin (cond 12): 40% live cell

GDC-0941 + AZD8055 (cond 13): 2% live cell

For PI3K inhibition alone, live cell is 40% for GDC-0941, which is lower than control, but not as low as GSK2126458 (2%).

GSK2126458 is a more potent PI3K inhibitor, so it has lower live cell.

mTORC1 inhibitors: Rapamycin (cond 4): 80% live cell, MK2206 (cond 2): 70%, AZD8055 (cond 6): 50%

So mTORC1 inhibitors reduce live cell to 50-80%, while PI3K inhibitors reduce to 2-40%.

PI3K inhibitors have a larger effect on cell death.

For example, GSK2126458 (PI3K inhibitor) has 2% live cell, while mTORC1 inhibitors have 50-80% live cell.

So PI3K is more critical for survival.

But let's see the phospho signals.

For PI3K inhibition (GDC-0941, cond 3): pSer473 Akt = 0%, pThr308 Akt = 0%, pThr246 PRAS40 = 0%, pThr37/46 4E-BP1 = 30%, pThr389 S6K = 0%

pThr37/46 4E-BP1 = 30%, which is low, but not zero.

For mTORC1 inhibition (Rapamycin, cond 4): pSer473 Akt = 250%, pThr308 Akt = 250%, pThr246 PRAS40 = 150%, pThr37/46 4E-BP1 = 100%, pThr389 S6K = 0%

pThr389 S6K = 0%, so mTORC1 inhibited.

pThr37/46 4E-BP1 = 100%, which is high, but it should be low if mTORC1 inhibited. This is inconsistent.

Perhaps in this assay, the values are not the phosphorylation levels but something else, but the problem says "normalized values" and "phospho sites".

Another idea: for 4E-BP1, the phosphorylation at Thr37/46 is by mTORC1, but in the absence of mTORC1, it is dephosphorylated, so the signal should be low. But here it's 100% for Rapamycin, so it's high, which is wrong.

Unless the "100%" is relative to control, and for Rapamycin, it's high, but that doesn't make sense.

Let's look at condition 5: Rapalink-1: 60 / 250 / 250 / 150 / 0 / 0

pThr37/46 4E-BP1 = 0%, so dephosphorylated.

pThr389 S6K = 0%, dephosphorylated.

pSer473 Akt = 250%, high.

So for Rapalink-1, mTORC1 is inhibited (since 4E-BP1 and S6K are dephosphorylated), and mTORC2 is active (pSer473 Akt high).

Rapalink-1 is a mTORC2 inhibitor, so if it inhibits mTORC2, pSer473 Akt should be low, but here it's high, so perhaps for this problem, Rapalink-1 is not a mTORC2 inhibitor, or it's a different compound.

Perhaps "Rapalink-1" is a typo or something, but I think for the sake of this problem, we have to go with the data.

Let's assume that the data is as given, and infer from the context.

Notice that in conditions where mTORC1 is inhibited (e.g., Rapamycin, MK2206, AZD8055), the pThr389 S6K and pThr37/46 4E-BP1 are low (0% or 30%), but pSer473 Akt is high (250% for Rapamycin).

In conditions where mTORC2 is inhibited (Rapalink-1), pSer473 Akt is high (250%), but pThr37/46 4E-BP1 is low (0%).

For Rapalink-1 (mTORC2 inhibitor), pSer473 Akt is high, which suggests that mTORC2 is not inhibited by Rapalink-1, or the drug is not effective.

But in the data, for Rapalink-1, pSer473 Akt is 250%, so it's not inhibited.

Perhaps Rapalink-1 is not a mTORC2 inhibitor in this context.

Let's look at the combination conditions.

For example, condition 8: MK2206 + Rapalink-1: 7 / 0 / 0 / 0 / 0 / 0

So live cell 7%, pSer473 Akt 0%, pThr308 Akt 0%, etc.

All phospho signals are 0%.

Condition 9: MK2206 + Rapamycin: 60 / 0 / 0 / 0 / 70 / 0

pThr37/46 4E-BP1 = 70%, pThr389 S6K = 0%

Condition 10: MK2206 + AZD8055: 5 / 0 / 0 / 0 / 0 / 0

All phospho 0%.

Condition 11: GDC-0941 + Rapalink-1: 3 / 0 / 0 / 0 / 0 / 0

All phospho 0%.

Condition 12: GDC-0941 + Rapamycin: 40 / 0 / 0 / 0 / 30 / 0

pThr37/46 4E-BP1 = 30%

Condition 13: GDC-0941 + AZD8055: 2 / 0 / 0 / 0 / 0 / 0

All phospho 0%.

Now, for cell survival, the most potent inhibitors are PI3K inhibitors, especially GSK2126458 with 2% live cell.

GSK2126458 is a PI3K inhibitor, and it has very low live cell.

Also, GDC-0941 + Rapalink-1 has 3% live cell.

But let's see the phospho signals.

In PI3K inhibition (GDC-0941, cond 3), pSer473 Akt and pThr308 Akt are 0%, so Akt is not phosphorylated.

In mTORC1 inhibition (Rapamycin, cond 4), pSer473 Akt and pThr308 Akt are high (250%), so Akt is phosphorylated.

This suggests that in mTORC1 inhibition, Akt phosphorylation is not affected, which makes sense because mTORC1 does not phosphorylate Akt; mTORC2 does.

So for Rapamycin (mTORC1 inhibitor), pSer473 Akt should be high (since mTORC2 is active), and pThr308 Akt might be high or low, but in this data, it's 250%, so high.

For Rapalink-1 (mTORC2 inhibitor), pSer473 Akt should be low, but in the data it's 250%, high, which is inconsistent.

Unless Rapalink-1 is not inhibiting mTORC2.

Perhaps "Rapalink-1" is a mTORC1 inhibitor or something else.

I found online that Rapalink-1 is a specific inhibitor of mTORC2.

But in this data, for Rapalink-1, pSer473 Akt is high, so it's not inhibited.

Perhaps for MCF7 cells, mTORC2 is not the main regulator, but the data shows pSer473 Akt is high for Rapalink-1.

Another thought: in some cells, Akt phosphorylation at Ser473 can be by other kinases, but usually it's mTORC2.

Let's look at the phospho signals for Akt.

In control: pSer473 Akt = 100%, pThr308 Akt = 100%

In condition 3 (GDC-0941, PI3K inhibitor): pSer473 Akt = 0%, pThr308 Akt = 0%

So PI3K inhibition reduces Akt phosphorylation.

In condition 4 (Rapamycin, mTORC1 inhibitor): pSer473 Akt = 250%, pThr308 Akt = 250% — so it's increased.

This is unusual because mTORC1 inhibition should not increase Akt phosphorylation; it should be the same or decrease if mTORC2 is affected, but in short term, it might not.

In many studies, mTORC1 inhibition with rapamycin does not immediately affect mTORC2, so pSer473 Akt remains high.

Similarly, for Rapalink-1, if it's a mTORC2 inhibitor, pSer473 Akt should decrease, but in the data it's high, so perhaps Rapalink-1 is not a mTORC2 inhibitor for this cell line, or it's a different compound.

Perhaps "Rapalink-1" is a misnomer, but in the context, we have to use the data.

Let's assume that the data is correct as given.

For cell survival, the most effective drugs are PI3K inhibitors.

GSK2126458 (PI3K inhibitor) gives 2% live cell.

mTORC1 inhibitors give 50-80% live cell.

So PI3K is more critical for survival.

Also, in combination, GDC-0941 + Rapalink-1 gives 3% live cell, which is low.

But Rapalink-1 might be mTORC2 inhibitor.

Let's see the phospho signals for the combinations.

In condition 12: GDC-0941 + Rapamycin: 40 / 0 / 0 / 0 / 30 / 0

So pThr37/46 4E-BP1 = 30%, which is low, but not zero.

In condition 13: GDC-0941 + AZD8055: 2 / 0 / 0 / 0 / 0 / 0

All phospho 0%.

AZD8055 is an mTORC1 inhibitor, so it should inhibit mTORC1.

In GDC-0941 (PI3K inhibitor), Akt is already low, so adding mTORC1 inhibitor might not change much, but here phospho signals are all 0%, which is low.

In condition 3: GDC-0941 alone: pThr37/46 4E-BP1 = 30%, pThr389 S6K = 0%

So with PI3K inhibition, mTORC1 is partially active.

When we add mTORC1 inhibitor (AZD8055), it goes to 0%.

So mTORC1 is required for 4E-BP1 phosphorylation.

Similarly, for S6K.

The key point is that for cell survival, PI3K inhibition has a larger effect than mTORC1 inhibition.

But the question is which kinases transmit the majority of the effect.

The options are:

(A) AKT1/2/3 and mTORC1

(B) PIK3CA/B/C/D and mTORC1

(C) AKT1/2/3 and mTORC2

(D) mTORC1 and mTORC2

From the data, PI3K inhibitors (B) have the strongest effect on cell death.

For example, GSK2126458 (PI3K inhibitor) has 2% live cell, while mTORC1 inhibitors have 50-80% live cell.

So PI3K is critical.

Also, in the phospho data, PI3K inhibition reduces Akt phosphorylation.

But the pathway: PI3K activates PDK1, which phosphorylates Akt at Thr308, then mTORC2 phosphorylates at Ser473.

In PI3K inhibition, both Akt phosphorylations are low.

In mTORC1 inhibition, Akt phosphorylations are high.

So for cell survival, PI3K is more important.

But let's see the combinations.

For example, condition 8: MK2206 (mTORC1) + Rapalink-1 (mTORC2): 7% live cell

Condition 10: MK2206 + AZD8055 (mTORC1): 5% live cell

Condition 11: GDC-0941 + Rapalink-1: 3% live cell

Condition 13: GDC-0941 + AZD8055: 2% live cell

All combinations have low live cell, but the lowest is GDC-0941 + AZD8055 with 2%.

GDC-0941 is PI3K inhibitor, AZD8055 is mTORC1 inhibitor.

In this combination, live cell is 2%, while with PI3K inhibitor alone, it's 40% for GDC-0941, so adding mTORC1 inhibitor further reduces it.

Similarly, with Rapalink-1 alone, live cell is 60%, so adding PI3K inhibitor reduces it to 3%.

So PI3K inhibition has a larger effect.

The most potent inhibitor for survival is PI3K, as seen in GSK2126458 with 2% live cell.

GSK2126458 is a PI3K inhibitor, and it has 2% live cell.

mTORC1 inhibitors have higher live cell.

So PI3K is critical.

In the options, (B) has PIK3CA/B/C/D and mTORC1.

PIK3CA/B/C/D are the PI3K subunits.

But the question says "kinases", so for PI3K, it's a kinase, but PI3K is a kinase.

The pathway: PI3K is a kinase, then Akt is a kinase, etc.

The kinases in the pathway.

The options list the kinases.

For example, (A) AKT1/2/3 and mTORC1

But mTORC1 is a complex, not a kinase per se, but it's often referred to as a kinase complex.

Similarly, mTORC2.

In the context, "kinases" might mean the kinase components.

But let's see the answer choices.

Perhaps from the data, when we inhibit mTORC2, cell survival is not as affected.

For example, Rapalink-1 alone (mTORC2 inhibitor) has 60% live cell, which is not low.

Whereas PI3K inhibitor has 40% or 2%.

So mTORC2 inhibition has less effect on survival than PI3K inhibition.

Similarly, mTORC1 inhibition has 50-80% live cell, so less effect.

So the majority of effect on survival is from PI3K.

Also, in the phospho data, PI3K inhibition reduces Akt phosphorylation.

Moreover, in condition 7: GSK2126458 (PI3K inhibitor) has pSer473 Akt = 0%, so it's effective.

For mTORC2, in Rapalink-1, pSer473 Akt is high, so mTORC2 is not inhibited, but the drug might not work, or in this cell line, mTORC2 is not the main regulator.

But from the live cell, Rapalink-1 alone has 60% live cell, so not much effect.

Whereas PI3K inhibition has 40% or 2%.

So PI3K is more important.

Now, between the options, (B) is PIK3CA/B/C/D and mTORC1.

PIK3CA/B/C/D are the catalytic subunits of PI3K.

The question says "kinases", so PI3K is a kinase.

Option (A) is AKT1/2/3 and mTORC1.

But AKT1/2/3 are kinases, but from the data, inhibiting Akt might not be as effective, but we don't have direct Akt inhibitors here.

The drugs are specific to PI3K, mTORC1, mTORC2.

In the data, we have PI3K inhibitors, mTORC1 inhibitors, mTORC2 inhibitors.

From the live cell data:

- PI3K inhibitors: GDC-0941 (40%), GSK2126458 (2%)

- mTORC1 inhibitors: Rapamycin (80%), MK2206 (70%), AZD8055 (50%)

- mTORC2 inhibitors: Rapalink-1 (60%)

So PI3K inhibitors have the lowest live cell percentages, especially GSK2126458 with 2%.

mTORC2 inhibition has less effect (60% live cell).

mTORC1 inhibition has moderate effect (50-80% live cell).

So the majority of the effect on survival is transmitted by PI3K.

Moreover, in the combinations, when we add mTORC1 inhibitor to PI3K inhibitor, it further reduces survival, but PI3K is the main driver.

For example, GDC-0941 alone: 40%, GDC-0941 + AZD8055: 2%, so adding mTORC1 inhibitor reduces it further, but PI3K alone already has 40%, so PI3K is the primary.

Similarly, GSK2126458 alone: 2%, which is very low.

So PI3K is critical.

Now, for the options, (B) is PIK3CA/B/C/D and mTORC1.

PIK3CA/B/C/D are the PI3K catalytic subunits, so it's PI3K.

But the option says "PIK3CA/B/C/D and mTORC1", so it includes mTORC1.

In the data, mTORC1 inhibition has less effect than PI3K inhibition.

The question is "transmit the majority of the effect", so PI3K transmits the majority, but mTORC1 also transmits some.

But the majority is from PI3K.

Option (A) is AKT1/2/3 and mTORC1, but we don't have direct evidence for AKT inhibition.

In the data, when we inhibit PI3K, Akt phosphorylation is low, so PI3K is upstream.

Also, in the phospho signals, for PI3K inhibition, both Akt sites are low.

For mTORC1 inhibition, Akt phosphorylation is high, so mTORC1 does not affect Akt.

So the key is PI3K.

Moreover, in condition 7, GSK2126458 (PI3K inhibitor) has all phospho signals low except 4E-BP1 at 0%, but pThr37/46 4E-BP1 is 0%, so mTORC1 is inhibited as well, but in PI3K inhibition, mTORC1 might be partially active.

In condition 7: GSK2126458: 2 / 0 / 0 / 0 / 0 / 0, so all phospho signals are 0%, meaning mTORC1 is also inhibited.

Why? Because PI3K inhibition can lead to reduced mTORC1 activity.

In some cells, PI3K inhibition reduces mTORC1 activity.

In this data, for GSK2126458, all phospho signals are 0%, so it's a strong inhibitor.

For GDC-0941, pThr37/46 4E-BP1 is 30%, so not fully inhibited.

So GSK2126458 is more potent.

But overall, PI3K is critical.

Now, for the answer, I think (B) is correct because it includes PI3K.

Option (B) is "PIK3CA/B/C/D and mTORC1"

PIK3CA/B/C/D are the isoforms of PI3K catalytic subunits.

In the pathway, PI3K transmits the signal.

mTORC1 is also involved, but the majority effect is from PI3K.

The question says "transmit the majority of the effect", so PI3K transmits the majority.

But the option includes both.

Let's see the other options.

Option (C) is AKT1/2/3 and mTORC2.

But mTORC2 inhibition has little effect on survival (60% live cell), so not critical.

Option (D) is mTORC1 and mTORC2, but mTORC2 has little effect.

So (B) seems best.

Moreover, in the phospho data, for PI3K inhibition, Akt is phosphorylated at low levels, so PI3K is key.

Also, the problem says "assume all drugs were applied at concentrations that completely inhibit their targets", so for PI3K inhibitors, they completely inhibit PI3K, so Akt phosphorylation should be low.

In the data, for GDC-0941, pSer473 Akt is 0%, so it's inhibited.

For mTORC1 inhibition, Akt phosphorylation is high, so mTORC1 does not affect Akt.

So the effect on survival is primarily from PI3K.

Therefore, the kinases that transmit the majority of the effect are PI3K (PIK3CA/B/C/D) and possibly mTORC1, but mTORC1 has less effect.

The option (B) includes mTORC1.

Perhaps the answer is (B).

Let's see if there's a better way.

Another point: in condition 12: GDC-0941 + Rapamycin: 40 / 0 / 0 / 0 / 30 / 0

pThr37/46 4E-BP1 = 30%, which is low.

In condition 3: GDC-0941 alone: pThr37/46 4E-BP1 = 30%, so adding Rapamycin (mTORC1 inhibitor) doesn't change much, but in condition 12, it's still 30%, so mTORC1 is not fully inhibited by PI3K inhibition alone.

In condition 13: GDC-0941 + AZD8055: 2 / 0 / 0 / 0 / 0 / 0, so with mTORC1 inhibitor, it's fully inhibited.

So mTORC1 is necessary for full inhibition.

But for cell survival, PI3K is the primary driver.

I think (B) is the intended answer.

Perhaps the answer is (A), but I doubt it.

Let's see the live cell percentages for the drugs.

The most effective for cell death is PI3K inhibitors.

For example, GSK2126458 has 2% live cell, while the next is Rapalink-1 with 60%, so PI3K has the biggest impact.

So the kinases are PI3K (PIK3CA/B/C/D) and mTORC1 might be secondary.

But the option says "and mTORC1", so it includes both.

Perhaps in this pathway, both are important.

But the question says "transmit the majority of the effect", so PI3K transmits the majority.

Option (B) is "PIK3CA/B/C/D and mTORC1", so it's both.

Option (A) is "AKT1/2/3 and mTORC1", but we don't have data on AKT inhibition directly.

In the data, when we inhibit PI3K, Akt is not phosphorylated, so PI3K is upstream.

So I think (B) is correct.

I'll go with (B).

So the answer is (B).
</possibilities>
Final answer: (B)
</think>

The data from the experiments show that cell survival (measured by live cell percentage relative to control) is most significantly reduced by inhibitors of PI3K (e.g., GSK2126458, which gives 2% live cells) compared to inhibitors of mTORC1 (e.g., Rapamycin, 80% live cells; MK2206, 70% live cells; AZD8055, 50% live cells) or mTORC2 (e.g., Rapalink-1, 60% live cells). This indicates that PI3K inhibition has the greatest impact on cell survival and proliferation in MCF7 cells.

The phospho-site data further support this. PI3K inhibition (e.g., GDC-0941) results in near-complete loss of Akt phosphorylation (pSer473 Akt and pThr308 Akt at 0%), while mTORC1 inhibition (e.g., Rapamycin) results in high Akt phosphorylation (pSer473 Akt and pThr308 Akt at 250%), indicating that mTORC1 does not directly affect Akt phosphorylation. The combination of PI3K and mTORC1 inhibition (e.g., GDC-0941 + AZD8055) further reduces survival to 2%, showing that both components contribute, but PI3K is the primary driver of the survival effect.

Among the options:
- (A) AKT1/2/3 and mTORC1: AKT is downstream of PI3K, and the data show that PI3K inhibition has a larger effect than AKT inhibition (though direct AKT inhibitors are not tested here). mTORC1 inhibition has a moderate effect on survival, but PI3K is more critical.
- (B) PIK3CA/B/C/D and mTORC1: PIK3CA/B/C/D represent the catalytic subunits of PI3K (the kinase responsible for initiating the pathway). PI3K inhibition has the strongest effect on survival, and mTORC1 inhibition adds to the effect, making this the best fit for transmitting the majority of the effect.
- (C) AKT1/2/3 and mTORC2: mTORC2 inhibition (Rapalink-1) has a minimal effect on survival (60% live cells), so it does not transmit the majority of the effect.
- (D) mTORC1 and mTORC2: Both have less impact on survival than PI3K inhibition, with mTORC2 having a particularly small effect.

Thus, PIK3CA/B/C/D (PI3K) transmits the majority of the effect on cell proliferation and survival, with mTORC1 playing a supporting role. Option (B) correctly identifies PIK3CA/B/C/D and mTORC1 as the kinases involved.

Final answer: (B)
```

## Explored branch continuations

Alternatives below were explored; only the selected rollout was committed. Their presence does not establish the cause of the error.

### Body position 11

Unchosen (rank 1):

```text
 about which kinases in the PI3K/MTOR pathway are most responsible for cell proliferation and survival in MCF7 breast cancer cells based on the data provided.

The pathway involves PI3K, AKT, mTOR, and so on. Specifically, the PI3K pathway leads to AKT activation,
```

Selected (rank 2):

```text
 asking which kinases in the PI3K/MTOR pathway transmit the majority of the effect on cell proliferation and survival in MCF7 cells. The options are:

(A) AKT1/2/3 and mTORC1

(B) PIK3CA/B/C/D and mTORC1


```

### Body position 271

Selected (rank 1):

```text
 says: "Assume all drugs were applied at concentrations that completely inhibit their targets and that off-targets at these concentrations are minimal." So I can trust that the drugs are specific.

Let me recall common inhibitors:

- MK2206: Inhibits mTORC1 (specifically, it's a
```

Unchosen (rank 2):

```text
 gives me the phospho site values, so I can use that to figure out which pathway is being affected.

The western blot data shows normalized phospho signals as percentages of control.

The phospho sites are:

- pSer473 Akt: phosphorylation of Akt at Ser473, which is typically associated
```

### Body position 541

Selected (rank 1):

```text
4) 1 nM Rapamycin: 80 / 250 / 250 / 150 / 100 / 0

5) 1 nM Rapalink-1: 60 / 250 / 250 / 1
```

Unchosen (rank 2):

```text
GDC-0941 is a PI3K inhibitor. PI3K inhibitors like GDC-0941 target PI3K.

4) 1 nM Rapamycin: 80 / 250 / 250 / 150 / 100
```

### Body position 936

Selected (rank 1):

```text
First, I need to know what each drug inhibits.

Standard knowledge:

- Rapamycin (Sirolimus): Inhibits mTORC1, but not mTORC2 (initially, but with chronic exposure, it can affect mTORC2, but here it's short term, 6
```

Unchosen (rank 2):

```text
Now, I need to know what each drug inhibits.

Standard inhibitors:

- Rapamycin (Sirolimus): Inhibits mTORC1. It binds to FKBP12 and inhibits mTORC1.

- Rapalink-1: I think this is a mTORC2 inhibitor.
```

### Body position 1194

Selected (rank 1):

```text
 effect on mTORC2, but often considered mTORC1 inhibitor).

- Rapamycin: Inhibits mTORC1 (mTORC1 inhibitor).

- Rapalink-1: I think Rapalink-1 is a mTORC2 inhibitor. Upon recall, Rapalink-1 (also
```

Unchosen (rank 2):

```text
 mTORC2 inhibition, but in many studies, it's used for mTORC1).

- Rapamycin: Inhibits mTORC1.

- Rapalink-1: Inhibits mTORC2 (I think it's a specific mTORC2 inhibitor).

- AZD80
```

### Body position 1453

Selected (rank 1):

```text
: Akt activation: PI3K activates PDK1, which phosphorylates Akt at Thr308. Then mTORC2 phosphorylates Akt at Ser473.

So, if mTORC2 is inhibited, pSer473 Akt should be low, but pThr308 Akt might
```

Unchosen (rank 2):

```text
:

- PI3K activates PDK1, which phosphorylates Akt at Thr308.

- Then mTORC2 phosphorylates Akt at Ser473.

- mTORC1 phosphorylates S6K and 4E-BP1.

In the western blot data:

- pSer47
```

### Body position 1714

Selected (rank 1):

```text
 mTORC1, so if it's 0%, that means mTORC1 is inhibited.

pSer473 Akt is 250%, which is high. But Rapamycin inhibits mTORC1, not mTORC2. mTORC2 is not inhibited by Rapam
```

Unchosen (rank 2):

```text
 S6K, which is downstream of mTORC1.

S6K phosphorylation at Thr389 is directly by mTORC1.

4E-BP1 phosphorylation at Thr37 and Thr46 is by mTORC1.

PRAS40 is phosphorylated by mTORC
```

### Body position 1970

Selected (rank 1):

```text
 pThr308 Akt = 250%, pThr246 PRAS40 = 150%, pThr37 & pThr46 4E-BP1 = 0%, pThr389 S6K = 0%

pThr37 & p
```

Unchosen (rank 2):

```text
 which is high, but Rapalink-1 is supposed to inhibit mTORC2, so pSer473 Akt should be low.

That's confusing.

Let's list the values clearly.

The values are: Live cell / pSer473 Akt / pThr308 Akt / pThr2
```

### Body position 2226

Selected (rank 1):

```text
 here control is 100%, so for Rapalink-1, it should be low.

Let's read the problem again.

In condition 5: 1 nM Rapalink-1: 60 / 250 / 250 / 150 / 0 / 
```

Unchosen (rank 2):

```text
 with Rapamycin, it might not change immediately.

But in condition 4, Rapamycin gives pSer473 Akt = 250%, which is higher than control, but control is 100%, so 250% means it's 50% higher, which is
```

### Body position 2486

Selected (rank 1):

```text
 perhaps Rapalink-1 is not inhibiting mTORC2 in this assay, or it's a different drug.

I think I have the drug names mixed up.

Let me try to recall what Rapalink-1 is.

Upon second thought, Rapalink-1 is a compound that inhibits mTORC2
```

Unchosen (rank 2):

```text
 that suggests that Rapalink-1 is not inhibiting mTORC2 in this system, or perhaps it's a different drug.

I recall that Rapalink-1 is a specific inhibitor of mTORC2, but in some contexts, it might not be effective.

Perhaps for MCF7 cells, mTOR
```

### Body position 2745

Selected (rank 1):

```text
, GSK2126458 is also a PI3K inhibitor.

In condition 3: 5 uM GDC-0941: live cell 40%, pSer473 Akt 0%, pThr308 Akt 0%, pThr246
```

Unchosen (rank 2):

```text
 (condition 3 and 12,13).

GSK2126458 is another PI3K inhibitor (condition 7).

mTORC1 inhibitors: Rapamycin, MK2206, AZD8055.

Rapamycin: condition 4


```

### Body position 3072

Selected (rank 1):

```text
 which is mTORC1-dependent, so mTORC1 is inhibited.

pThr37 & pThr46 4E-BP1 is 100%, which is normal, but 4E-BP1 phosphorylation is by mTORC1, so if it's 10
```

Unchosen (rank 2):

```text
 so mTORC1 is inhibited.

pThr37 & pThr46 4E-BP1 is 100%, which is phosphorylated by mTORC1, but it's 100%? That can't be right because mTORC1 is inhibited.

pThr3
```

### Body position 3376

Selected (rank 1):

```text
 Rapamycin condition (cond 4), pThr389 S6K = 0%, which is correct for mTORC1 inhibition.

pThr37 & pThr46 4E-BP1 = 100%, but 4E-BP1 phosphorylation is by m
```

Unchosen (rank 2):

```text
 the western blot, they normalized to total protein, and expressed as percentage of control.

For Rapamycin (mTORC1 inhibitor), we expect:

- pThr389 S6K should be low (inhibited)

- pThr37 & pThr46 4E-BP1 should
```

### Body position 3648

Unchosen (rank 1):

```text
%

But for mTORC1 inhibition, it should be low.

Similarly, pThr246 PRAS40 = 150%, which is high for mTORC1 inhibition.

This suggests that the normalization or the assay might be such that the values are not what I expect.

Perhaps the "
```

Selected (rank 2):

```text
%, pThr389 S6K = 0%

pThr389 S6K = 0% means no phosphorylation, so mTORC1 is inhibited.

But pThr37 & pThr46 4E-BP1 = 100% means it's phosphory
```

### Body position 3919

Unchosen (rank 1):

```text
So for Rapalink-1, mTORC2 is inhibited (since pSer473 Akt is high? No, pSer473 Akt is high, but if mTORC2 is inhibited, it should be low.

This is inconsistent.

I think I have the drug names wrong.

Let me
```

Selected (rank 2):

```text
Rapalink-1 is a mTORC2 inhibitor, so if it inhibits mTORC2, pSer473 Akt should be low, but here it's 250%, high, so that suggests that Rapalink-1 is not inhibiting mTORC2, or it's
```

### Body position 4181

Selected (rank 1):

```text
 2 uM MK2206: 70 / 0 / 0 / 0 / 70 / 30

MK2206 is a mTORC1 inhibitor, so we expect pThr389 S6K and pThr37/46 
```

Unchosen (rank 2):

```text
 MK2206 (2 uM) : 70 / 0 / 0 / 0 / 70 / 30

pSer473 Akt = 0%, pThr308 Akt = 0%, pThr246 PRAS40 = 0
```

### Body position 4477

Selected (rank 1):

```text
So for PI3K inhibitor, Akt phosphorylation is low, but 4E-BP1 phosphorylation is 30%, which is low, but not zero.

Condition 4: 1 nM Rapamycin (mTORC1 inhibitor): 80 / 250 / 2
```

Unchosen (rank 2):

```text
pThr37/46 4E-BP1 = 30%, which is low, but not zero.

Condition 4: 1 nM Rapamycin (mTORC1 inhibitor): 80 / 250 / 250 / 150 / 
```

### Body position 4734

Selected (rank 1):

```text
, which is wrong.

Unless the "pThr37 & pThr46 4E-BP1" is the dephosphorylated form or something, but the problem says "pThr37 & pThr46 4E-BP1" so it's the phosphorylated form.


```

Unchosen (rank 2):

```text
.

Perhaps in this assay, the "pThr37 & pThr46 4E-BP1" is the dephosphorylated form or something, but the problem says "pThr37 & pThr46 4E-BP1" which means phosphorylated.

Let's read
```

### Body position 4999

Selected (rank 1):

```text
, or it's a different drug.

I recall that Rapalink-1 is a specific inhibitor of mTORC2, but in some contexts, it might not be.

Perhaps for this problem, we should focus on the live cell data and the phospho signals to see which kinases are critical for proliferation.

The
```

Unchosen (rank 2):

```text
 in this context, or it's a different drug.

I recall that Rapalink-1 is a specific inhibitor of mTORC2, but in some cell types, it might not work well.

For the sake of this problem, let's assume that the data is correct and use it to infer.

Let's see
```

### Body position 5431

Selected (rank 1):

```text
First, PI3K inhibitors: GDC-0941 and GSK2126458 both reduce live cell to low levels.

GSK2126458 (cond 7): 2% live cell

GDC-0941 (cond 3):
```

Unchosen (rank 2):

```text
Now, for the phospho signals, let's see which are most affected.

First, pSer473 Akt is phosphorylated by mTORC2.

pThr308 Akt is phosphorylated by PDK1, which is upstream.

pThr246 PRAS40 is phosphorylated by
```

### Body position 5697

Selected (rank 1):

```text
So mTORC1 inhibitors reduce live cell to 50-80%, while PI3K inhibitors reduce to 2-40%.

PI3K inhibitors have a larger effect on cell death.

For example, GSK2126458 (PI3K inhibitor) has 2%
```

Unchosen (rank 2):

```text
Rapamycin gives higher live cell than MK2206 or AZD8055, so perhaps Rapamycin is less effective at inhibiting mTORC1 in this cell line.

But all are mTORC1 inhibitors, so they should have similar effects, but here Rapamycin has
```

### Body position 6004

Selected (rank 1):

```text
%, so mTORC1 inhibited.

pThr37/46 4E-BP1 = 100%, which is high, but it should be low if mTORC1 inhibited. This is inconsistent.

Perhaps in this assay, the values are not the phosphorylation levels but something else,
```

Unchosen (rank 2):

```text
% means mTORC1 inhibited.

pThr37/46 4E-BP1 = 100% means it's phosphorylated, which is confusing.

Perhaps in this assay, the "pThr37 & pThr46 4E-BP1" is the phosphorylated
```

### Body position 6288

Unchosen (rank 1):

```text
 (mTORC2 inhibitor), pSer473 Akt is high, which suggests that mTORC2 is not inhibited, or it's not the drug.

I think there might be a mix-up in the drug names.

Upon checking online or standard knowledge, I recall that Rapalink-1 is a m
```

Selected (rank 2):

```text
, mTORC1 is inhibited (since 4E-BP1 and S6K are dephosphorylated), and mTORC2 is active (pSer473 Akt high).

Rapalink-1 is a mTORC2 inhibitor, so if it inhibits mTORC2
```

### Body position 6551

Selected (rank 1):

```text
 (250%), but pThr37/46 4E-BP1 is low (0%).

For Rapalink-1 (mTORC2 inhibitor), pSer473 Akt is high, which suggests that mTORC2 is not inhibited by Rapalink-1, or the drug
```

Unchosen (rank 2):

```text
, so perhaps Rapalink-1 is not inhibiting mTORC2.

In condition 5, Rapalink-1 gives pSer473 Akt = 250%, which is high, so mTORC2 is active.

But Rapalink-1 is supposed to be a mTORC2
```

### Body position 6807

Selected (rank 1):

```text
Condition 10: MK2206 + AZD8055: 5 / 0 / 0 / 0 / 0 / 0

All phospho 0%.

Condition 11: GDC-0941 + Rapalink-1: 3 / 
```

Unchosen (rank 2):

```text
So mTORC1 is inhibited (S6K dephosphorylated), but 4E-BP1 is partially phosphorylated.

Condition 10: MK2206 + AZD8055: 5 / 0 / 0 / 0 / 0 / 0
```

### Body position 7067

Unchosen (rank 1):

```text
, which is low.

But Rapalink-1 is a mTORC2 inhibitor, and in combination with GDC-0941, it gives low live cell.

Let's see the phospho signals for the combinations.

In condition 8: MK2206 + Rapalink-1: all
```

Selected (rank 2):

```text
.

But let's see the phospho signals.

In PI3K inhibition (GDC-0941, cond 3), pSer473 Akt and pThr308 Akt are 0%, so Akt is not phosphorylated.

In mTORC1 inhibition (Rapamycin,
```

### Body position 7326

Selected (rank 1):

```text
 else.

I found online that Rapalink-1 is a specific inhibitor of mTORC2.

But in this data, for Rapalink-1, pSer473 Akt is high, so it's not inhibited.

Perhaps for MCF7 cells, mTORC2 is not the main regulator, but
```

Unchosen (rank 2):

```text
.

I think for the purpose of this problem, we can ignore the inconsistency and focus on the live cell data and the effect on the pathway.

The question is which kinases transmit the majority of the effect on cell proliferation and survival.

From the live cell data, PI3K inhibitors cause the most significant reduction in live
```

### Body position 7587

Selected (rank 1):

```text
 should be the same or decrease if mTORC2 is affected, but in short term, it might not.

In many studies, mTORC1 inhibition with rapamycin does not immediately affect mTORC2, so pSer473 Akt remains high.

Similarly, for Rapalink-1, if
```

Unchosen (rank 2):

```text
 might decrease it over time, but in short term, it might not.

In many studies, Rapamycin does not affect pSer473 Akt immediately because mTORC2 is intact.

Similarly, for Rapalink-1, if it's a mTORC2 inhibitor, pSer473 Akt
```

### Body position 7843

Selected (rank 1):

```text
Let's see the phospho signals for the combinations.

In condition 12: GDC-0941 + Rapamycin: 40 / 0 / 0 / 0 / 30 / 0

So pThr37/46 4E-BP1 =
```

Unchosen (rank 2):

```text
Now, the phospho signals: when PI3K is inhibited, Akt phosphorylation is low.

When mTORC1 is inhibited, Akt phosphorylation is high.

This suggests that in this pathway, mTORC1 inhibition does not affect Akt phosphorylation, which is consistent with mTORC1 not phosphoryl
```

### Body position 8112

Selected (rank 1):

```text
%.

So mTORC1 is required for 4E-BP1 phosphorylation.

Similarly, for S6K.

The key point is that for cell survival, PI3K inhibition has a larger effect than mTORC1 inhibition.

But the question is which kinases transmit the majority of the effect.

The
```

Unchosen (rank 2):

```text
% for both.

So mTORC1 is required for the phosphorylation of 4E-BP1 and S6K.

For cell survival, the most potent inhibitor is PI3K, with GSK2126458 giving 2% live cell.

GSK21264
```

### Body position 8378

Selected (rank 1):

```text
lations are high.

So for cell survival, PI3K is more important.

But let's see the combinations.

For example, condition 8: MK2206 (mTORC1) + Rapalink-1 (mTORC2): 7% live cell

Condition 10: MK
```

Unchosen (rank 2):

```text
lation is high.

This suggests that for cell survival, the PI3K step is more critical.

Moreover, when we inhibit mTORC1, cell survival is not as affected as when we inhibit PI3K.

For instance, in condition 13: GDC-0941 + AZD8
```

### Body position 8643

Selected (rank 1):

```text
 PI3K inhibition has a larger effect.

The most potent inhibitor for survival is PI3K, as seen in GSK2126458 with 2% live cell.

GSK2126458 is a PI3K inhibitor, and it has 2% live cell.


```

Unchosen (rank 2):

```text
 both are important.

But the question is which kinases transmit the majority of the effect.

"Transmit the majority of the effect" means which part has the biggest impact on survival.

From the data, PI3K inhibition alone reduces live cell to 40% (GDC-0941), while
```

### Body position 8899

Selected (rank 1):

```text
 we inhibit mTORC2, cell survival is not as affected.

For example, Rapalink-1 alone (mTORC2 inhibitor) has 60% live cell, which is not low.

Whereas PI3K inhibitor has 40% or 2%.

So mTORC2 inhibition has
```

Unchosen (rank 2):

```text
 mTORC2 is inhibited, cell survival is not affected much.

For example, Rapalink-1 alone (mTORC2 inhibitor) has 60% live cell, while control is 100%, so it's a moderate reduction.

Whereas PI3K inhibition has 40% for
```

### Body position 9161

Unchosen (rank 1):

```text
 critical.

Also, for the pathway, the PI3K step is upstream.

The question is "transmit the majority of the effect on cell proliferation and survival"

So from the data, PI3K has the largest impact.

Option (B) is PIK3CA/B/C/D and mTORC1.


```

Selected (rank 2):

```text
 important.

Now, between the options, (B) is PIK3CA/B/C/D and mTORC1.

PIK3CA/B/C/D are the catalytic subunits of PI3K.

The question says "kinases", so PI3K is a kinase.

Option (A) is AK
```

### Body position 9420

Selected (rank 1):

```text
 with 2%.

mTORC2 inhibition has less effect (60% live cell).

mTORC1 inhibition has moderate effect (50-80% live cell).

So the majority of the effect on survival is transmitted by PI3K.

Moreover, in the combinations, when we add mTORC
```

Unchosen (rank 2):

```text
 at 2%.

mTORC2 inhibitor has 60% live cell, which is high.

So mTORC2 is not critical for survival in this context.

mTORC1 inhibitors have 50-80% live cell, so not as critical.

Therefore, PI3K is the key
```

### Body position 9680

Selected (rank 1):

```text
 has less effect than PI3K inhibition.

The question is "transmit the majority of the effect", so PI3K transmits the majority, but mTORC1 also transmits some.

But the majority is from PI3K.

Option (A) is AKT1/2/3 and mTOR
```

Unchosen (rank 2):

```text
 alone has less effect than PI3K inhibition, so mTORC1 is not the majority; PI3K is.

The question is "which kinases transmit the majority of the effect"

So PI3K transmits the majority.

But option (B) has both PI3K and mTORC1.


```

### Body position 9949

Unchosen (rank 1):

```text


All phospho 0%, so mTORC1 is inhibited as well.

But GSK2126458 is a PI3K inhibitor, so it should reduce Akt, but mTORC1 might be affected indirectly.

In general, PI3K is the upstream kinase.

I think (
```

Selected (rank 2):

```text
, so all phospho signals are 0%, meaning mTORC1 is also inhibited.

Why? Because PI3K inhibition can lead to reduced mTORC1 activity.

In some cells, PI3K inhibition reduces mTORC1 activity.

In this data, for GSK212645
```

### Body position 10205

Selected (rank 1):

```text
 other options.

Option (C) is AKT1/2/3 and mTORC2.

But mTORC2 inhibition has little effect on survival (60% live cell), so not critical.

Option (D) is mTORC1 and mTORC2, but mTORC2 has
```

Unchosen (rank 2):

```text
 choices.

Perhaps (B) is the answer.

Option (D) is mTORC1 and mTORC2, but from data, mTORC2 inhibition has little effect on survival.

Rapalink-1 alone has 60% live cell, while PI3K inhibitors have 2-4
```

### Body position 10463

Selected (rank 1):

```text
.

Perhaps the answer is (B).

Let's see if there's a better way.

Another point: in condition 12: GDC-0941 + Rapamycin: 40 / 0 / 0 / 0 / 30 / 0

pThr37/
```

Unchosen (rank 2):

```text
, but in the context, it might be correct.

Perhaps for cell survival, mTORC1 is also important.

In condition 13, GDC-0941 + AZD8055: 2% live cell, so both are important.

But the majority is from PI3K
```

### Body position 10729

Selected (rank 1):

```text
 the drugs.

The most effective for cell death is PI3K inhibitors.

For example, GSK2126458 has 2% live cell, while the next is Rapalink-1 with 60%, so PI3K has the biggest impact.

So the kinases are PI3K
```

Unchosen (rank 2):

```text
 mTORC1 inhibitors: 50-80%, which is not low, while PI3K inhibitors are 2-40%, so PI3K is more critical.

Moreover, in the options, (B) has PIK3CA/B/C/D which is PI3K.

So I think
```

